20-F: SOPHiA GENETICS Sees Revenue Rise 19%, Navigates Patent Suit

SOPHiA GENETICS SA reported a 19% increase in revenue to $77.3 million for 2025, driven by platform adoption and analysis volume, while navigating an ongoing patent infringement lawsuit and increasing net losses.

Summary

• Revenue increased by 19% to $77.3 million for the year ended December 31, 2025, from $65.2 million in 2024.
• Net loss widened to $79.0 million in 2025, compared to $62.5 million in 2024.
• Gross profit grew by 19% to $52.1 million in 2025, maintaining a stable gross margin of 67%.
• SOPHiA DDM Platform analysis volume increased by 11% to 391,698 in 2025 from 352,628 in 2024.
• Core Genomics Customers grew to 528 as of December 31, 2025, from 472 in 2024.
• Net Dollar Retention (NDR) improved to 115% as of December 31, 2025, from 104% in 2024, with an annualized churn rate of 0.1%.
• The company secured an additional $25.0 million in term loan commitments from Perceptive Credit Agreement in January 2026, with $12.5 million immediately available.
• An At-The-Market (ATM) offering program was established in August 2025, raising $1.1 million in net proceeds in 2025 and an additional $14.1 million through February 20, 2026.
• The U.S. District Court vacated the FDA's Laboratory Developed Tests (LDT) Final Rule in April 2025, which was formally reinstated in September 2025, maintaining the prior regulatory framework.
• The company is defending against patent infringement claims by Guardant Health in the U.K. and EU, incurring $2.4 million in legal expenses in the second half of 2025, but won a provisional measures ruling in the UPC Paris Local Division, with Guardant ordered to pay EUR 400,000 in interim costs.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed report. While revenue growth and customer adoption are positive, the widening net losses, increased operating expenses, and ongoing litigation present significant financial headwinds and uncertainties.

Positives

• Strong revenue growth of 19% year-over-year, reaching $77.3 million in 2025.
• Consistent gross margin of 67% in both 2025 and 2024.
• Significant increase in SOPHiA DDM Platform analysis volume by 11% in 2025.
• Growth in Core Genomics Customers to 528 in 2025, indicating an expanding user base.
• Improved Net Dollar Retention (NDR) of 115% in 2025, demonstrating increased revenue from existing customers and low churn (0.1%).
• Successful rejection of Guardant Health's application for provisional measures by the UPC Paris Local Division, with an interim cost award of EUR 400,000 to be paid by Guardant.
• Vacating of the FDA's LDT Final Rule maintains the existing regulatory framework, reducing potential compliance burdens and costs for the company's RUO products.
• Expansion of the Perceptive Credit Agreement by $25.0 million, providing additional capital flexibility.
• Successful capital raise through an ATM offering, generating $1.1 million in 2025 and $14.1 million through February 20, 2026.
• Strategic leadership transition with Ross Muken becoming CEO and Dr. Jurgi Camblong transitioning to Executive Chairman, effective July 1, 2026.

Negatives

• Net loss increased significantly by 26% to $79.0 million in 2025 from $62.5 million in 2024.
• Accumulated deficit grew to $519.3 million as of December 31, 2025.
• Cash and cash equivalents decreased to $70.3 million in 2025 from $80.2 million in 2024.
• Operating loss increased by 7% to $70.9 million in 2025.
• Selling and marketing costs increased by 23% to $36.1 million in 2025.
• General and administrative costs increased by 12% to $52.6 million in 2025, partly due to $2.4 million in legal expenses for the Guardant Health litigation.
• Interest income decreased by 44% to $1.9 million in 2025 due to lower cash balances and decreasing market interest rates.
• Interest expense increased by 138% to $4.6 million in 2025 due to additional borrowings.
• Foreign exchange shifted from a gain of $3.5 million in 2024 to a loss of $3.4 million in 2025.
• Ongoing patent infringement litigation with Guardant Health, which could result in significant costs and diversion of management attention, and potential injunctive relief in the U.K. and EU.
• Uncertainty regarding potential changes to the SEC's Foreign Private Issuer (FPI) definition, which could increase compliance obligations and costs.
• Significant tax loss carryforwards of $448.2 million, with $444.0 million unrecognized as deferred tax assets due to uncertainty of future taxable profits.

Risks

• Inability to successfully expand features, applications, and data modalities of the SOPHiA DDM Platform.
• Challenges with the acquisition, development, enhancement, and deployment of necessary data analytics platform technologies, including integration of new genomics test kits and expansion into markets without suitable cloud infrastructure.
• Failure to expand sales and marketing capabilities cost-effectively, potentially hindering revenue growth.
• Uncertainty regarding coverage and reimbursement status for newly developed applications and products, particularly in new diagnostic and therapeutic categories, which could limit commercial potential.
• Inability to maintain current relationships and establish new ones with hospitals, reference/specialty laboratories, and biopharmaceutical companies, potentially reducing revenue prospects.
• High dependence on senior management and qualified personnel, with risks if unable to retain and attract such talent.
• Rapid industry change could render the SOPHiA DDM Platform and related solutions obsolete if continuous innovation and improvement are not maintained.
• Intense competition from companies with greater financial resources and market share, potentially hindering successful competition.
• Cybersecurity or data privacy breaches, unauthorized access, or denial-of-service attacks could lead to costs, revenue loss, liabilities, reputational harm, and decreased platform use.
• Inability to obtain, maintain, defend, and enforce patent and other intellectual property protection, or if the scope is insufficient, allowing competitors to commercialize similar technologies.
• Reliance on third-party licensors for patent rights; failure of licensors to protect patents or comply with license obligations could adversely affect business.
• Exposure to claims of infringing, misappropriating, or violating third-party intellectual property rights, including the ongoing Guardant Health litigation, which could result in substantial defense costs, settlement payments, and diversion of management attention.
• Continued net losses and expectation of future losses, with no assurance of achieving or sustaining profitability.
• Need to raise additional capital, which may not be available on acceptable terms and could dilute shareholder value or impose restrictive covenants.
• Indebtedness under the Perceptive Credit Agreement and associated restrictive covenants could adversely affect financial condition and flexibility.
• Fluctuations in quarterly and annual operating results, potentially causing stock price volatility.
• Inability to sufficiently reduce costs to achieve sustainable gross margins, particularly with increasing computational and storage-related costs.
• Risks associated with customized products, including unsaleable inventory if orders are cancelled.
• Limitations on the ability to use tax loss carryforwards in various jurisdictions.
• Exposure to economic, political, regulatory, and other risks associated with international operations, including global trends towards pharmaceutical pricing, differing regulatory requirements, and currency exchange rate fluctuations.
• Product liability lawsuits, potentially leading to substantial liabilities or marketing limitations.
• Failure to maintain an effective system of internal controls over financial reporting, impacting financial reporting accuracy and fraud prevention.
• Risks related to handling hazardous materials and compliance with environmental safety regulations.
• Challenges to informed consent for clinical trial data and samples, hindering product development.
• Failure to comply with ongoing FDA or comparable regulatory authority requirements, or unanticipated product problems, leading to restrictions or market withdrawal.
• Changes in tariffs, potentially increasing cost of revenue and operating expenses.
• Risks associated with the use of artificial intelligence (AI) and machine learning (ML) algorithms, including performance degradation, liability, and evolving regulatory frameworks.
• Risks related to the use of open-source software, potentially requiring disclosure of proprietary code or litigation.
• Changes in U.S. patent law diminishing patent value.
• Risks related to the accounting treatment of pension and other post-employment benefit plans.
• Volatility in the market price of ordinary shares.
• Potential adverse effects on share price from future sales of ordinary shares.
• Limitations on capital raising flexibility due to Swiss law and articles of association.
• Lack of certain Swiss law protections for shareholders in public takeover offers due to exclusive Nasdaq listing.
• Difficulties for U.S. shareholders to obtain judgments or enforce civil liabilities against the company or its non-U.S. executive officers/directors.
• Anti-takeover provisions in articles of association.
• Potential Passive Foreign Investment Company (PFIC) status for U.S. investors.
• Loss of foreign private issuer status, increasing compliance costs.
• Loss of emerging growth company status by end of 2026, increasing compliance burden.
• Reputational, regulatory, legal, and financial risks related to public ESG commitments and statements.

Future Outlook

The company aims to achieve cash flow positive status in the next few years by continuing to invest in research and development to expand the SOPHiA DDM Platform's features, applications, and data modalities, particularly for multimodal data analytics across various disease areas. It plans to expand selling and marketing efforts to drive new customer adoption with clinical customers and biopharmaceutical companies, establish and maintain collaborations, and obtain regulatory clearances for IVD applications. The company expects to continue incurring net losses in the foreseeable future due to these investments.

Management Comments

• "We observed an increase in chargeable analysis volume of 11% for the year ended December 31, 2025, as compared to the year ended December 31, 2024. This increase is primarily attributable to increased usage from our existing customers as well as new customers onboarded onto our platform, with outsized growth in our Hematological Oncology (HemOnc) applications and primarily related to strong volume growth in EMEA and NORAM."
• "The year-over-year increase in revenue growth momentum is attributable to growth across our existing customer base as well as higher average selling prices of our products. The annualized churn rate was 0.1%, which was lower than 2024 as a result of the relative size of lost customers."
• "We intend to vigorously defend ourselves against these claims [Guardant Health litigation]."
• "The Board of Directors believes that the Company has sufficient financial resources to meet all of its obligations for at least the next twelve months."

Industry Context

StockSavvy.ai notes that SOPHiA GENETICS operates in the rapidly evolving precision medicine and healthcare technology sector, characterized by increasing demand for data-driven insights from complex multimodal data sets. The company's decentralized platform model positions it to capitalize on the growing digitization of healthcare data, particularly in genomics and radiomics. The vacating of the FDA's LDT Final Rule provides a stable, albeit scrutinized, regulatory environment for its Research Use Only (RUO) products, which is favorable compared to the increased compliance burden that would have been imposed. The ongoing patent litigation with Guardant Health highlights the intense intellectual property competition within the diagnostics and bioinformatics space, where companies like Tempus Labs, F. Hoffmann-La Roche, and Caris Life Sciences are also active. The company's focus on AI/ML-powered multimodal analytics aligns with broader industry trends towards more comprehensive diagnostic and therapeutic approaches.

Comparison to Industry Standards

• SOPHiA GENETICS' 115% Net Dollar Retention (NDR) is strong, indicating effective "land and expand" strategy and customer satisfaction, comparable to high-growth SaaS companies in the tech sector.
• The company's gross margin of 67% is competitive within the software and data analytics segment of the healthcare technology industry, often exceeding margins of traditional diagnostic kit manufacturers.
• The company's platform has supported the analysis of approximately 2.3 million genomic profiles and has been utilized in over 2,712 peer-reviewed publications, demonstrating significant scientific validation and adoption within the research community, a key metric for credibility in the genomics field.
• The company's ability to deploy cloud infrastructure in new geographies within one to four weeks (or twelve weeks if infrastructure is absent) showcases operational agility, which is a competitive advantage compared to traditional hardware-heavy diagnostic providers.
• The company's stated accuracy for genomic variant detection (e.g., SNVs >99.9%, Indels >99.5%, CNVs >99.0%, Fusions >99.0%) is benchmarked against orthogonal assays like Sanger Sequencing, MLPA, array CGH, and digital PCR, indicating high analytical performance crucial for clinical genomics.

Management Changes

Corporate Governance

Legal Proceedings

• Guardant Health filed patent infringement suits in the U.K. (July 2025) and EU Unified Patent Court (August 2025) alleging infringement by SOPHiA GENETICS' MSK-Access liquid biopsy test, seeking monetary damages and injunctive relief.
• The UPC Paris Local Division rejected Guardant's application for provisional measures on January 23, 2026, and ordered Guardant to pay EUR 400,000 in interim costs by March 10, 2026. Guardant appealed this decision on February 9, 2026.
• SOPHiA GENETICS is pursuing reimbursement of additional legal costs exceeding EUR 200,000 in separate cost proceedings.
• The U.K. proceedings remain pending.
• The company incurred $2.4 million in legal expenses in the second half of 2025 related to these cases.

Related Party Transactions

• Indemnification Agreements: Entered into with executive officers and directors, requiring indemnification to the fullest extent permitted by law.
• Related Person Transaction Policy: Adopted policy requiring audit committee or board approval/ratification of related person transactions, considering commercial reasonableness and company's best interests.

Stakeholder Impact

• Shareholders: Potential for dilution from future equity raises (ATM offering, warrants), stock price volatility, and impact from ongoing litigation. Benefits from revenue growth and improved NDR.
• Employees: Continued investment in R&D and sales force expansion creates job opportunities. Share-based compensation plans are a key part of retention. Leadership transition may bring new strategic direction.
• Customers (Hospitals, Labs, Biopharma): Benefit from expanded platform features, multimodal analytics, and new applications. Continued focus on accuracy, rapid turnaround, and cost-efficiency. Potential for new CDx solutions through partnerships.
• Suppliers/Partners: Continued collaboration with consumables, hardware, and cloud service providers (e.g., Microsoft, IDT, Qiagen, NEB, Watchmaker). Partnership with Myriad Genetics for CDx development.
• Creditors (Perceptive Credit Holdings IV, LP): Increased debt exposure with additional term loan commitments, secured by company assets. Warrants provide equity upside.
• Regulatory Bodies (FDA, EMA, MHRA, Swissmedic, ANVISA): Ongoing compliance with evolving medical device and data privacy regulations (e.g., IVDR, FADP, potential FPI definition changes). Litigation outcomes could influence regulatory scrutiny.

Next Steps

• Continue to invest in scientific innovation to expand and enhance the SOPHiA DDM Platform's features, applications, and data modalities.
• Drive new customer adoption with clinical customers worldwide, particularly in North America and Asia-Pacific.
• Increase utilization within the existing clinical customer base through a "land and expand" model.
• Leverage the platform and database to drive adoption by biopharmaceutical companies, including developing new offerings.
• Establish and grow industry collaborations across the healthcare ecosystem with instrument, reagent, and software companies.
• Vigorously defend against patent infringement claims by Guardant Health in the U.K. and EU, and pursue reimbursement of additional legal costs.
• Monitor developments regarding the SEC's potential changes to the Foreign Private Issuer (FPI) definition.
• Ross Muken to become CEO and Dr. Jurgi Camblong to become Executive Chairman, effective July 1, 2026.
• Modify quality systems to meet QMSR by February 2, 2026.
• Ensure full compliance with IVDR Article 5(5) for in-house devices by May 2030.

Key Dates

Recommendation

SOPHiA GENETICS demonstrates strong revenue growth and customer engagement, with an improving Net Dollar Retention. The vacating of the FDA's LDT rule is a positive for its current business model. However, the company continues to incur significant net losses and operating expenses, and its cash position has decreased. The ongoing patent litigation with Guardant Health, despite a favorable provisional ruling, introduces substantial legal costs and uncertainty, including the risk of injunctive relief. While the recent capital raises provide liquidity, the path to profitability remains challenging. Investors should hold, monitoring the litigation outcome, FPI status developments, and the company's ability to translate platform growth into sustainable profitability.

Keywords

Genomics, Precision Medicine, AI, Machine Learning, Data Analytics, Biopharma, Oncology, Rare Diseases, NGS, Radiomics, SOPHiA DDM Platform, SEC Filing, 20-F, Healthcare Technology, Clinical Genomics, IVD, RUO, Patent Litigation, Capital Raise, Financial Results, Switzerland, Nasdaq